Cervical cancer is a malignancy arising in the cervix, often linked to persistent high-risk HPV infection. It remains an important global women's health cancer with preventable burden through vaccination and screening.
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.
A retrospective review found tisotumab vedotin produced similar response rates in radiated and non-radiated cervical cancer lesions. In the 29-patient cohort, median overall survival was 11.0 months and median progression-free survival was 2.8 months.
New research shows HPV vaccination provides sustained protection against invasive cervical cancer for over a decade, with vaccinated individuals showing significantly lower cancer rates. The study found 79% lower risk for those vaccinated before age 17, with protection lasting 13-15 years. Cervical cancer remains a major global health challenge, particularly in regions like India and the Caribbean where infection rates are high.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
The FDA has approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying esophageal cancer patients eligible for Merck's KEYTRUDA immunotherapy. This marks the eighth FDA-approved indication for this diagnostic test with KEYTRUDA. The test helps identify patients whose tumors express PD-L1 for potential treatment with the anti-PD-1 therapy.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
Ten63 Therapeutics announced strategic investment from Chugai Venture Fund and the Gates Foundation, bringing total funding to more than $45 million to advance its BEYOND AI drug discovery platform targeting previously undruggable proteins.
Phase II trial finds adding gemcitabine to cisplatin does not improve outcomes in muscle-invasive bladder cancer, while separate study shows gemcitabine-lobaplatin interventional embolization benefits advanced cervical cancer patients.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597083 |
Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors |
RECRUITING | NA |
| NCT07593066 |
PRIORITY Study in Cervical Cancer |
NOT_YET_RECRUITING | |
| NCT07586826 |
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors |
RECRUITING | PHASE2 |
| NCT07584161 |
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer |
NOT_YET_RECRUITING | NA |
| NCT07581873 |
Education and Health in Women With Cervical Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT07576842 |
Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV |
NOT_YET_RECRUITING | NA |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
| NCT07547267 |
The Effect of Vaginal Dilator Use |
COMPLETED | NA |
| NCT07524322 |
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07521163 |
Effect of Health Belief Model-Based Education on Cervical Cancer Knowledge and HPV Vaccine Attitudes in Women |
NOT_YET_RECRUITING | NA |
